Haemonetics’ (HAE) Buy Rating Reaffirmed at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Haemonetics (NYSE:HAE) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $88.00 target price on the medical instruments supplier’s stock.

A number of other brokerages also recently weighed in on HAE. Barrington Research increased their price target on Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. CJS Securities upgraded Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. JPMorgan Chase & Co. raised their target price on Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research note on Friday, December 12th. Citigroup dropped their price target on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, October 7th. Finally, Robert W. Baird increased their price target on Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $84.10.

Haemonetics Price Performance

Haemonetics stock opened at $82.01 on Friday. The stock’s 50 day moving average is $77.66 and its 200 day moving average is $65.97. Haemonetics has a one year low of $47.31 and a one year high of $87.32. The firm has a market cap of $3.84 billion, a P/E ratio of 23.98, a P/E/G ratio of 1.58 and a beta of 0.29. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. During the same quarter last year, the business earned $1.12 EPS. The company’s revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, research analysts expect that Haemonetics will post 4.55 EPS for the current year.

Institutional Investors Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently modified their holdings of HAE. True Wealth Design LLC lifted its holdings in shares of Haemonetics by 6,700.0% in the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 335 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 396 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 165 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of Haemonetics by 216.4% during the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 567 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Haemonetics by 20,925.0% during the third quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 837 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics News Roundup

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Acquisition adds next‑generation large‑bore vascular closure tech (PerQseal Elite), broadening Haemonetics’ product set for structural heart and endovascular procedures. This expansion supports revenue cross‑sell and addresses a growing procedural market. Article Title
• Positive Sentiment: Deal strengthens Haemonetics’ vascular closure market presence and positions it in a niche (sutureless, bioabsorbable closure for up to 26F) that’s relevant to structural‑heart device growth. This is a clear strategic tuck‑in that could accelerate top‑line growth if adoption scales. Article Title
• Positive Sentiment: Analyst and market sentiment supportive: BTIG reaffirmed a “buy” with an $88 price target, signaling incremental analyst confidence that could help investor appetite. Article Title
• Positive Sentiment: Independent research notes Haemonetics’ streak of earnings surprises and suggests the company has the mix to beat again, which can lift sentiment alongside M&A news. Article Title
• Neutral Sentiment: Multiple outlets are reporting the deal and confirming the headline terms (up to €185M), underscoring that the transaction is public and priced; broader market reaction will depend on integration pacing and revenue contribution over time. Article Title
• Negative Sentiment: Potential risks: integration/execution risk and any financing impact (Haemonetics’ balance sheet and leverage could be affected depending on how the deal was funded). These factors could weigh on near‑term margins or sentiment if costs or slower adoption emerge.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.